{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:18:50Z","timestamp":1787735930489,"version":"build-2784847793"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Utidelone is a genetically engineered epothilone analog and microtubule-stabilizing agent developed in China. It demonstrates antitumor activity in recurrent or metastatic breast cancer after anthracycline and taxane failure. In the pivotal phase III BG01-1323L trial, utidelone plus capecitabine improved progression-free and overall survival versus capecitabine alone; however, peripheral neuropathy occurred in 59% of combination patients, including grade 3 in 22%, versus 8% and less than 1%, respectively, with capecitabine alone. Clinically, neuropathy may impair fine motor function, gait, sleep, and other daily activities, effects not fully captured by toxicity grades alone. Prospective and real-world studies confirm that peripheral neuropathy remains the principal treatment-limiting toxicity of utidelone. Utidelone-specific mechanistic evidence is emerging but remains limited. A 2025 mouse study linked utidelone-induced mechanical and cold allodynia to TRPA1 upregulation and oxidative stress in dorsal root ganglia. Beyond this single preclinical finding, proposed mechanisms--including altered microtubule dynamics, impaired axonal transport, mitochondrial dysfunction, and neuroinflammation--are largely extrapolated from taxane and platinum research. Their relevance to utidelone-induced numbness or persistent deficits in humans remains speculative. Neither ASCO nor ESMO-EONS-EANO recommends routine pharmacologic prophylaxis for chemotherapy-induced peripheral neuropathy (CIPN). Duloxetine has the strongest evidence base for treating established painful CIPN but has not been evaluated specifically for utidelone-associated neuropathy. A small randomized trial found that electroacupuncture produced greater symptomatic improvement than mecobalamin in patients with utidelone-associated neuropathy, although larger confirmatory trials are needed. Evidence supporting monosialotetrahexosylganglioside (GM1), exercise, acupuncture, cryotherapy, compression therapy, or neuromodulation remains preliminary, indirect, or context-dependent. We distinguish utidelone-specific evidence from evidence extrapolated from taxane-, platinum-, and mixed-CIPN populations, because broader CIPN findings are frequently applied to patients receiving utidelone despite uncertain direct applicability. On the basis of available evidence and established CIPN principles, we propose a practical framework integrating pretreatment neurologic and risk assessment, cycle-by-cycle monitoring, symptom-directed supportive care, fall prevention, rehabilitation, and individualized modification of anticancer treatment. Prospective studies are needed to define the onset, cumulative dose\u2013toxicity relationship, persistence, recovery trajectory, and modifiable risk factors of utidelone-associated neuropathy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1927392","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:35:46Z","timestamp":1787733346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Utidelone-associated chemotherapy-induced peripheral neuropathy: an evidence-stratified narrative review of mechanisms, risk identification, and management strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Sili","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Nanchong Central Hospital Affiliated with North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Nanchong Central Hospital Affiliated with North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, Nanchong Central Hospital Affiliated with North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30088-8","article-title":"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial","volume":"18","author":"Zhang","year":"2017","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.600","article-title":"Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial","volume":"32","author":"Xu","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-016-0297-7","article-title":"Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients","volume":"9","author":"Zhang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sopen.2023.10.008","article-title":"Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: a multicenter real-world study","volume":"16","author":"Bi","year":"2023","journal-title":"Surg Open Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12935-024-03608-7","article-title":"Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer","volume":"24","author":"Feng","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251368684","article-title":"Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study","volume":"17","author":"Hu","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04990-x","article-title":"Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study","author":"Liu","year":"2026","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.62347\/OLES9793","article-title":"Utidelone-based therapy in advanced or metastatic solid tumors after failure of standard therapies: a prospective, multicenter, single-arm trial","volume":"14","author":"Qiao","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.160","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"6","author":"Cavaletti","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7290","article-title":"Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments","volume":"17","author":"McCrary","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139394","article-title":"Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy","volume":"10","author":"Ferdousi","year":"2015","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006083","article-title":"Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations","volume":"91","author":"Gewandter","year":"2018","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13603.x","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.70319","article-title":"Utility of vibration perception thresholds as a biomarker of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"30","author":"Khan","year":"2026","journal-title":"Eur J Pain"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/17448069251377633","article-title":"Utidelone induces mechanical and cold allodynia in mice via TRPA1 activation","volume":"21","author":"Gao","year":"2025","journal-title":"Mol Pain"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328323","article-title":"Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence","volume":"94","author":"Park","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00481","article-title":"A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fukuda","year":"2017","journal-title":"Front Neurosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21874","article-title":"Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy","volume":"43","author":"Park","year":"2011","journal-title":"Muscle Nerve"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2013.05.008","article-title":"Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy","volume":"37","author":"LaPointe","year":"2013","journal-title":"Neurotoxicology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.irn.2019.05.001","article-title":"Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy","volume":"145","author":"Trecarichi","year":"2019","journal-title":"Int Rev Neurobiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.06.008","article-title":"Pharmacological modulation of the mitochondrial electron transport chain in paclitaxel-induced painful peripheral neuropathy","volume":"16","author":"Griffiths","year":"2015","journal-title":"J Pain"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.626687","article-title":"Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fumagalli","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.006","article-title":"Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy","volume":"73","author":"Lees","year":"2017","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4370","article-title":"Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade","volume":"73","author":"Trevisan","year":"2013","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/112_2014_18","article-title":"The TRPA1 channel in inflammatory and neuropathic pain and migraine","volume":"167","author":"Nassini","year":"2014","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41598-017-05784-1","article-title":"Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms","volume":"7","author":"Imai","year":"2017","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2017.88","article-title":"Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics","volume":"13","author":"Argyriou","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1590","article-title":"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101","volume":"18","author":"Baldwin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1842379","article-title":"Why pharmacogenomic biomarkers for chemotherapy-induced peripheral neuropathy fail: a systematic review of genetic associations, replication, and clinical translation","volume":"17","author":"Maganti","year":"2026","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-026-05078-y","article-title":"Prevalence and factors associated with chemotherapy induced peripheral neuropathy among adult patients with cancer at Mbarara Regional Cancer Centre: a cross-sectional study","author":"Avaga","year":"2026","journal-title":"BMC Neurol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-4013-0","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support Care Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S526405","article-title":"Effects of electroacupuncture and mecobalamin for utidelon-induced peripheral neuropathy in breast cancer patients: a randomized controlled clinical trial","volume":"18","author":"Lu","year":"2025","journal-title":"J Pain Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.008","article-title":"A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients","volume":"101","author":"Bao","year":"2018","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0681","article-title":"Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: A randomized clinical trial","volume":"3","author":"Bao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1690446","article-title":"Efficacy and safety of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients: A systematic review and meta-analysis","volume":"16","author":"Huang","year":"2025","journal-title":"Front Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2026.103254","article-title":"Effectiveness of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy-related pain: A systematic review and network meta-analysis","volume":"83","author":"Kobayashi","year":"2026","journal-title":"Eur J Oncol Nurs"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.524223","article-title":"Ganglioside monosialic acid alleviates peripheral neuropathy induced by utidelone plus capecitabine in metastatic breast cancer from a phase III clinical trial","volume":"10","author":"Xu","year":"2020","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12885-021-08884-4","article-title":"Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: A meta-analysis with trial sequential analysis","volume":"21","author":"Wu","year":"2021","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-19","article-title":"Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors","volume":"11","author":"Zhu","year":"2013","journal-title":"World J Surg Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx178","article-title":"Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: Prospective self-controlled trial","volume":"110","author":"Hanai","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2424-8","article-title":"Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy","volume":"23","author":"Pachman","year":"2015","journal-title":"Support Care Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04881-3","article-title":"Scrambler therapy for chemotherapy neuropathy: A randomized phase II pilot trial","volume":"28","author":"Loprinzi","year":"2020","journal-title":"Support Care Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2009.04.004","article-title":"The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency","volume":"88","author":"Scalabrino","year":"2009","journal-title":"Prog Neurobiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4646-1","article-title":"Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative","volume":"169","author":"Zhang","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/15347354231185110","article-title":"Neurological outcomes of chemotherapy-induced peripheral neuropathy in patients with cancer: A systematic review and meta-analysis","volume":"22","author":"Suzuki","year":"2023","journal-title":"Integr Cancer Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:35:47Z","timestamp":1787733347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1927392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1927392"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1927392","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1927392"}}